Research programme: cancer therapeutics - Cleave Biosciences

Drug Profile

Research programme: cancer therapeutics - Cleave Biosciences

Alternative Names: Inhibitors of p97 ATPase activity - Cleave Biosciences; p97 inhibitors - Cleave Biosciences

Latest Information Update: 07 Nov 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cleave Biosciences
  • Class Small molecules
  • Mechanism of Action Adenosine triphosphatase inhibitors; Protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Oct 2013 Preclinical trials in Cancer in USA (PO)
  • 22 Oct 2013 Pharmacodynamics data from a preclinical trial in Cancer presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
  • 11 Oct 2011 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top